[1]陈 超,范卫君.骨与软组织肉瘤肺转移的治疗进展[J].介入放射学杂志,2019,28(05):499-503.
 CHEN Chao,FAN Weijun..Recent progress in the treatment of lung metastases from bone and soft tissue sarcomas[J].journal interventional radiology,2019,28(05):499-503.
点击复制

骨与软组织肉瘤肺转移的治疗进展()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
28
期数:
2019年05期
页码:
499-503
栏目:
综 述
出版日期:
2019-05-25

文章信息/Info

Title:
Recent progress in the treatment of lung metastases from bone and soft tissue sarcomas
作者:
陈 超 范卫君
Author(s):
CHEN Chao FAN Weijun.
The Second Hospital of Shandong University, Jinan, Shandong Province 250033, China
关键词:
【关键词】 骨与软组织肉瘤肺转移 外科切除 局部消融
文献标志码:
A
摘要:
【摘要】 肺是骨与软组织肉瘤最常见的转移部位,是导致其死亡的主要原因。早期、积极并综合的干预,可以有效地延长肺转移瘤患者的生存期。目前手术切除及化疗是肉瘤肺转移的主要治疗手段,但存在其局限性。肺转移瘤的局部治疗,包括局部消融、立体定向放疗、放射性粒子植入术等取得了良好的治疗效果。肺转移瘤的局部消融治疗效果已经不亚于外科手术切除。本文对近年来骨与软组织肉瘤肺转移的治疗进展作一综述,并希望借此促进多学科诊治团队对肉瘤肺转移瘤的认知,推广局部消融治疗在肺转移瘤中的应用,也为更多患者带来获益。

参考文献/References:

[1] Falk AT, Moureau- Zabotto L, Ouali M, et al. Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group[J]. Clin Oncol, 2015, 27: 48- 55.
[2] Gadd MA, Casper ES, Woodruff JM, et al. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma[J]. Ann Surg, 1993, 218: 705- 712.
[3] Snyder CL, Saltzman DA, Ferrell KL, et al. A new approach to the resection of pulmonary osteosarcoma metastases: results of aggressive metastasectomy[J]. Chir Organi Mov, 1990, 75: 265- 269.
[4] Mori K, Ando K, Heymann D. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases[J]. Expert Rev Anticancer Ther, 2008, 8: 151- 159.
[5] Smith R, Pak Y, Kraybill W, et al. Factors associated with actual long- term survival following soft tissue sarcoma pulmonary metastasectomy[J]. EJSO, 2009, 35: 356- 361.
[6] Treasure T, Macbeth F. Doubt about effectiveness of lung metastasectomy for sarcoma[J]. J Thorac Cardiovasc Surg, 2015, 149: 93- 94.
[7] Treasure T, Fiorentino F, Scarci M, et al. Pulmonary metastasectomy for sarcoma: a systematic review of reported outcomes in the context of Thames Cancer Registry data[J]. BMJ Open, 2012, 2: e001736.
[8] Roth JA, Putnam JB, JR, et al. Differing determinants of prognosis following resection of pulmonary metastases from osteogenic and soft tissue sarcoma patients[J]. Cancer, 1985, 55: 1361- 1366.
[9] Harting MT, Blakely ML, Jaffe N, et al. Long- term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma[J]. J Pediatr Surg, 2006, 41: 194- 199.
[10] Patrini D, Panagiotopoulos N, Lawrence DA. Surgical management of lung metastases[J]. Br J Hosp Med, 2017, 78: 192- 198.
[11] Castagnetti M, Delarue A, Gentet JC. Optimizing the surgical management of lung nodules in children with osteosarcoma: thoracoscopy for biopsies, thoracotomy for resections[J]. Surg Endosc, 2004, 18: 1668- 1671.
[12] Gossot D, Radu C, Girard P, et al. Resection of pulmonary metastases from sarcoma: can some patients benefit from a less invasive approach?[J]. Ann Thorac Surg, 2009, 87: 238- 243.
[13] Park JS, Kim HK, Choi YS, et al. Outcomes after repeated resection for recurrent pulmonary metastases from colorectal cancer[J]. Ann Oncol, 2010, 21: 1285- 1289.
[14] Kim S, Ott HC, Wright CD, et al. Pulmonary resection of metastatic sarcoma: prognostic factors associated with improved outcomes[J]. Ann Thorac Surg, 2011, 92: 1780- 1786.
[15] Suzuki M, Iwata T, Ando S, et al. Predictors of long- term survival with pulmonary metastasectomy for osteosarcomas and soft tissue sarcomas[J]. J Cardiovasc Surg(Torino), 2006, 47: 603- 608.
[16] Bacci G, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions[J]. J Surg Oncol, 2008, 98: 415- 420.
[17] Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phaseⅡstudy of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer(FNCLCC) French Sarcoma Group Study[J]. Oncologist, 2012, 17: 1213- 1220.
[18] Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase Ⅱ trial[J]. J Clin Oncol, 2002, 20: 2824- 2831.
[19] Tascilar M, Loos WJ, Seynaeve C, et al. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas[J]. Oncologist, 2007, 12: 1351- 1360.
[20] Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase Ⅱ study on neo- adjuvant chemotherapy for ‘high- risk’ adult soft- tissue sarcoma[J]. Eur J Cancer, 2001, 37: 1096- 1103.
[21] Blackmon SH, Shah N, Roth JA, et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long- term survival[J]. Ann Thorac Surg, 2009, 88: 877- 885.
[22] Olivier T, Pop D, Chouiter Djebaili AC, et al. Treating metastatic sarcomas locally: a paradoxe, a rationale, an evidence?[J]. Crit Rev Oncol Hematol, 2015, 95: 62- 77.
[23] Nakamura T, Matsumine A, Yamakado K, et al. Lung radiofrequency ablation in patients with pulmonary metastases from musculoskeletal sarcomas[J]. Cancer, 2009, 115: 3774- 3781.
[24] Palussiere J, Italiano A, Descat E, et al. Sarcoma lung metastases treated with percutaneous radiofrequency ablation: results from 29 patients[J]. Ann Surg Oncol, 2011, 18: 3771- 3777.
[25] Koelblinger C, Strauss S, Gillams A. Outcome after radiofrequency ablation of sarcoma lung metastases[J]. Cardiovasc Intervent Radiol, 2014, 37: 147- 153.
[26] Sato T, Iguchi T, Hiraki T, et al. Radiofrequency ablation of pulmonary metastases from sarcoma: single- center retrospective evaluation of 46 patients[J]. Jpn J Radiol, 2017, 35: 61- 67.
[27] de Baere T. Lung tumor radiofrequency ablation: where do we stand?[J]. Cardiovasc Intervent Radiol, 2011, 34: 241- 251.[28] Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention- to- treat, multicentre clinical trial(the RAPTURE study)[J]. Lancet Oncol, 2008, 9: 621- 628.
[29] Simon CJ, Dupuy DE, Dipetrillo TA, et al. Pulmonary radiofre- quency ablation: long- term safety and efficacy in 153 patients[J]. Radiology, 2007, 243: 268- 275.
[30] Sano Y, Kanazawa S, Gobara H, et al. Feasibility of percutaneous radiofrequency ablation for intrathoracic malignancies: a large single- center experience[J]. Cancer, 2007, 109: 1397- 1405.
[31] Kashima M, Yamakado K, Takaki H, et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center’s experiences[J]. AJR Am J Roentgenol, 2011, 197: W576- W580.
[32] Hiraki T, Mimura H, Gobara H, et al. Repeat radiofrequency ablation for local progression of lung tumors: does it have a role in local tumor control?[J]. J Vasc Interv Radiol, 2008, 19: 706- 711.
[33] Hinshaw JL, Lubner MG, Ziemlewicz TJ, et al. Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation: what should you use and why?[J]. Radiographics, 2014, 34: 1344- 1362.
[34] Brace CL, Hinshaw JL, Laeseke PF, et al. Pulmonary thermal ablation: comparison of radiofrequency and microwave devices by using gross pathologic and CT findings in a swine model[J]. Radiology, 2009, 251: 705- 711.
[35] Qi H, Fan W. Value of ablation therapy in the treatment of lung metastases[J]. Thorac Cancer, 2018, 9: 199- 207.
[36] Navarria P, Ascolese AM, Tomatis S, et al. Stereotactic body radiotherapy(SBRT) in lung oligometastatic patients: role of local treatments[J]. Radiat Oncol, 2014, 9: 91.
[37] Dhakal S, Corbin KS, Milano MT, et al. Stereotactic body radiotherapy for pulmonary metastases from soft tissue sarcomas: excellent local lesion control and improved patient survival[J]. Int J Radiat Oncol Biol Phys, 2010, 78: S614.
[38] Navarria P, Ascolese AM, Cozzi L, et al. Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma[J]. Eur J Cancer, 2015, 51: 668- 674.
[39] Baumann BC, Nagda SN, Kolker JD, et al. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: a potential alternative to resection[J]. J Surg Oncol, 2016, 114: 65- 69.
[40] Soyfer V, Corn BW, Shtraus N, et al. Single- institution experience of SBRT for lung metastases in sarcoma patients[J]. Am J Clin Oncol, 2017, 40: 83- 85.
[41] Imamura F, Chatani M, Nakayama T, et al. Percutaneous brachytherapy for small- sized non- small cell lung cancer[J]. Lung Cancer, 1999, 24: 169- 174.
[42] Johnson M, Colonias A, Parda D, et al. Dosimetric and technical aspects of intraoperative 125I brachytherapy for stage Ⅰnon- small cell lung cancer[J]. Med Phys, 2006, 33: 2089- 2090.
[43] Huo X, Huo B, Wang H, et al. Percutaneous computed tomography- guided permanent 125I implantation as therapy for pulmonary metastasis[J]. J Contemp Brachytherapy, 2018, 10: 132- 141.



相似文献/References:

[1]李茂全,颜志平,周康荣,等.中晚期肝癌根治术后介入放射学治疗的临床研究[J].介入放射学杂志,1994,(02):79.
[2]郭玮平,王 杰,管一伟,等.肝动脉化疗栓塞联合微波消融与外科根治性切除治疗小肝癌的对照研究[J].介入放射学杂志,2019,28(07):642.
 GUO Weiping,WANG Jie,GUAN Yiwei,et al.TACE combined with microwave ablation versus radical surgical resection for the treatment of small HCC: a comparison study[J].journal interventional radiology,2019,28(05):642.

备注/Memo

备注/Memo:
(收稿日期:2018-07-17)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2019-05-11